saxenda glp-1 pharmaceutical company overview FDA Approves First Generic Liraglutide for Weight Loss Saxenda® (liraglutide) Injection 3 mg

2 (T2DM) , 11 3 .78 Multi agonists In recent years, the development of dual and triple agonists related to GLP-1 has been vigorously pursued.124,125,126 The design concept of these multi-agonists is to simultaneously regulate multiple key metabolic pathways to achieve more effective control over blood sugar, body weight, and overall metabolic health.43 Currently, these drugs are primarily in the development and clinical trial stages, but preliminary research results have shown their potential powerful effects in reducing blood sugar and body weight.127,128 Dual agonists Dual agonists target both the GLP-1R and another specific receptor.124,129 A common combination is GLP-1 with GIP or insulin-like growth factor.130 For example, a popular dual agonist, tirzepatide (brand name Mounjaro), activates both GLP-1 and GIPR.124 GLP-1, by activating its receptor, increases insulin secretion and reduces glucagon secretion, thereby lowering blood sugar levels.131,132,133 Additionally, GLP-1 helps to delay gastric emptying and suppress appetite, aiding in weight management.121,134 GIP, another insulin secretion agonist, helps release insulin, particularly after eating, enhancing the effects of GLP-1 and thereby improving the overall therapeutic efficacy of the drug.125,130 In 2022, tirzepatide was approved by the FDA for the treatment of T2DM in the United States.135,136 It is considered a significant breakthrough in diabetes treatment and is also being studied for the treatment of obesity due to its significant weight loss effects.135 Tirzepatide is developed by Eli Lilly and has proven to provide superior blood sugar control and significant weight loss, making it particularly valuable in the treatment of T2DM.136,137,138 Research and clinical trials have shown that tirzepatide not only improves blood sugar levels but also has a positive impact on cardiovascular risk factors.139,140,141 Although dual agonists show advantages in efficacy, their safety and tolerability continue to be a focus of ongoing monitoring.141 Common side effects include gastrointestinal reactions, such as nausea and vomiting, which are typically more common during the initial stages of treatment.141,142 The Phase III clinical trials of tirzepatide were conducted in 77 research centers across seven countries, including the United States, Brazil, and Japan.143 The trials recruited adult participants with T2DM and significantly reduced body weight and improved blood sugar control in these patients.143 The safety profile of tirzepatide is similar to other drugs in its class, providing an effective new treatment option for patients with T2DM and obesity

Additionally, they signal to your brain that you are full, reducing appetite and caloric intake

These developments, coupled with Opdivos inclusion in BMSs Growth Portfolio, which saw revenues increase by 17% to $22.56 billion, maintain its pivotal role in the companys oncology strategy

This week, Im digging into why and what it means for any woman in midlife who isnt getting the metabolic results she expected

But don't worrythere are natural ways to combat nausea and get back to feeling your best

Appetite suppression kicks in within 30-60 minutes, helping portion control during meals